The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwHRMM 2024 | Selecting between CAR-Ts and bispecifics for patients with HRMM who are triple-class exposed
Roberto Mina, MD, University of Turin, Turin, Italy, discusses selecting between therapies for patients with high-risk multiple myeloma (HRMM) who are triple-class exposed. He considers access, patient fitness, and disease characteristics when selecting between CAR-Ts and bispecific antibodies. This discussion took place at the 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM 2024), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
